Popular Trials
Growth Hormone Releasing Hormone Analog
Tesamorelin for Non-alcoholic Fatty Liver Disease
This trial is investigating whether a drug called tesamorelin, which helps the body produce growth hormone, can reduce the amount of fat in the liver and improve liver inflammation in people with obesity and nonalcoholic fatty liver disease.
Vitamin E Derivative
Tocotrienol for End Stage Liver Disease
This trial is to see if a previous trial's results were accurate- that Tocotrienol (TCT) could help end stage liver disease / cirrhosis patients by taking 2 capsules of it (200mg) or placebo twice a day for 3 years.
GLP-1 Receptor Agonist
NNC0194-0499 + Semaglutide for Fatty Liver Disease
This trial is testing if combining two medicines, NNC0194-0499 and semaglutide, can reduce liver damage in people with non-alcoholic steatohepatitis (NASH). Semaglutide, already used for diabetes and weight loss, and NNC0194-0499 work differently but may be more effective together. Another combination being tested includes semaglutide and NNC0174-0833. Participants will receive regular injections and undergo liver biopsies to measure the treatment's effectiveness.
Popular Filters
Trials for Non-alcoholic Fatty Liver Disease Patients
Behavioral Intervention
Intermittent Fasting for Non-alcoholic Fatty Liver Disease
This trial is studying if time-restricted, intermittent fasting can help reduce liver fat in adults who are not obese. The idea is that fasting will make the body burn fat for energy instead of sugar, which might help decrease liver fat. Intermittent fasting has shown favorable effects on body weight and relevant indicators of liver health in several reports.
Thiazolidinedione
Low-Dose Pioglitazone for NASH
This trial is testing a small daily dose of pioglitazone in patients with type 2 diabetes and a specific liver condition called NASH. The goal is to see if this medication can improve their liver health by helping their bodies manage blood sugar and fat levels better.
Thyroid Hormone Receptor Agonist
Resmetirom for Fatty Liver Disease
This trial is testing a medication called MGL-3196 to see if it can help treat patients with NASH and liver fibrosis. The medication works by reducing fat and inflammation in the liver, which can help heal and protect it from further damage.
SGLT2 Inhibitor
SGLT2 Inhibitors for Non-Alcoholic Fatty Liver Disease
This trial tests empagliflozin, a medication that helps remove extra sugar through urine, in adolescents with obesity and a specific liver condition (NAFLD). The medication works by blocking a protein in the kidneys to help remove sugar from the body. Empagliflozin has been shown to reduce body weight, improve glucose tolerance, and decrease blood pressure in various studies.
Trials for NAFLD Patients
Behavioral Intervention
Intermittent Fasting for Non-alcoholic Fatty Liver Disease
This trial is studying if time-restricted, intermittent fasting can help reduce liver fat in adults who are not obese. The idea is that fasting will make the body burn fat for energy instead of sugar, which might help decrease liver fat. Intermittent fasting has shown favorable effects on body weight and relevant indicators of liver health in several reports.
Thiazolidinedione
Low-Dose Pioglitazone for NASH
This trial is testing a small daily dose of pioglitazone in patients with type 2 diabetes and a specific liver condition called NASH. The goal is to see if this medication can improve their liver health by helping their bodies manage blood sugar and fat levels better.
Thyroid Hormone Receptor Agonist
Resmetirom for Fatty Liver Disease
This trial is testing a medication called MGL-3196 to see if it can help treat patients with NASH and liver fibrosis. The medication works by reducing fat and inflammation in the liver, which can help heal and protect it from further damage.
SGLT2 Inhibitor
SGLT2 Inhibitors for Non-Alcoholic Fatty Liver Disease
This trial tests empagliflozin, a medication that helps remove extra sugar through urine, in adolescents with obesity and a specific liver condition (NAFLD). The medication works by blocking a protein in the kidneys to help remove sugar from the body. Empagliflozin has been shown to reduce body weight, improve glucose tolerance, and decrease blood pressure in various studies.
Phase 3 Trials
Thyroid Hormone Receptor Agonist
Resmetirom for Fatty Liver Disease
This trial is testing a medication called MGL-3196 to see if it can help treat patients with NASH and liver fibrosis. The medication works by reducing fat and inflammation in the liver, which can help heal and protect it from further damage.
Thyroid Hormone Receptor Agonist
Resmetirom for Non-alcoholic Fatty Liver Disease
This trial is studying the safety and tolerability of Resmetirom, a pill taken regularly. It involves patients who are already using this medication. Resmetirom helps manage certain health conditions by targeting specific parts of the body and has shown to reduce liver fat in patients with non-alcoholic steatohepatitis (NASH) in previous studies.
Hormone Therapy
Estrogen Therapy for NASH in Postmenopausal Women
This trial will study the effect of the hormone estradiol on non-alcoholic steatohepatitis (NASH) in post-menopausal women. NASH is a growing epidemic in the United States with limited treatment options.
Glucagon-like peptide-1 receptor agonist
Semaglutide for Non-alcoholic Steatohepatitis
This trial is studying a medication called semaglutide in patients with NASH. Semaglutide is a well-known medication used to treat type 2 diabetes, and participants will either receive semaglutide or a dummy medication, with no way of knowing which they're getting. The study will last for 5 years, during which participants will have to inject themselves weekly and will have 21 clinic visits and 9 phone calls with clinical staff. Some of the clinic visits may last more than one day.
Growth Factor
Efruxifermin for NASH
This trial is testing a medication called efruxifermin (EFX) to see if it can help people with specific liver conditions. These conditions are hard to treat with current methods. EFX aims to improve liver health by reducing inflammation and fat buildup in the liver.
Trials With No Placebo
Behavioural Intervention
Diabetes Prevention & Education for Prediabetes
This trial aims to reduce risk of type 2 diabetes in people with pre-diabetes by increasing access to lifestyle interventions. We will also study changes in body fat & liver fat in those who complete the program.
Behavioral Intervention
Intermittent Fasting for Non-alcoholic Fatty Liver Disease
This trial is studying if time-restricted, intermittent fasting can help reduce liver fat in adults who are not obese. The idea is that fasting will make the body burn fat for energy instead of sugar, which might help decrease liver fat. Intermittent fasting has shown favorable effects on body weight and relevant indicators of liver health in several reports.
Cardiac Glycoside
Digoxin for Alcoholic Hepatitis
This trial is testing whether a drug called digoxin is effective at treating people with severe alcohol-related liver damage. Patients will be given the drug or a placebo and monitored to see if their liver damage improves.
Thyroid Hormone Receptor Agonist
Resmetirom for Non-alcoholic Fatty Liver Disease
This trial is studying the safety and tolerability of Resmetirom, a pill taken regularly. It involves patients who are already using this medication. Resmetirom helps manage certain health conditions by targeting specific parts of the body and has shown to reduce liver fat in patients with non-alcoholic steatohepatitis (NASH) in previous studies.
View More Related Trials
Frequently Asked Questions
Introduction to fatty liver
What are the top hospitals conducting fatty liver research?
When it comes to addressing the challenges posed by fatty liver disease, several hospitals are leading the way in research and clinical trials. Massachusetts General Hospital in Boston is at the forefront with six ongoing trials dedicated to this condition, and an impressive track record of 24 completed studies since their first recorded fatty liver trial in 2010. In sunny Lakewood Ranch, Florida Research Institute has also made significant contributions, with six active fatty liver trials and 17 previous studies conducted since starting their pioneering investigation in 2016.
Meanwhile, South Texas Research Institute in Edinburg takes pride in its commitment to combating fatty liver disease as well. They currently have six ongoing clinical trials focused on this condition, building upon their portfolio of 14 completed studies since initiating their first trial just a couple of years ago in 2019. Similarly devoted to making strides against fatty liver disease is the Inland Empire Liver Foundation located in Rialto. With five active clinical trials underway and a solid base of knowledge from conducting 28 previous studies since recording their inaugural trial back when they started delving into these issues around 2015.
Lastly but certainly not least is Louisiana Research Center LLC based out Shreveport; despite smaller operation scale they're actively participating with five concurrent clinical tests while already having successfully accomplished twelve former investigations regarding treatment methods tackling such challenging cases ever since opening doors for patients back around same time frame namelysince circa year:2-15
These hospitals demonstrate unwavering commitment toward unraveling secrets behind-fatty-liver related problems thereby proving continual dedication towards informing medical fraternity about novel solutions which may prove beneficial for multitude affected by this escalating health issue nationwide
Which are the best cities for fatty liver clinical trials?
When it comes to fatty liver clinical trials, several cities have emerged as leaders in research and development. Miami, Florida, offers the highest number of active trials with 59 ongoing studies focusing on innovative treatments like IVA337, Study 1 ALN-HSD Low Dose, and Obeticholic Acid. San Antonio, Texas also boasts 59 active trials exploring potential breakthroughs such as VK2809, AXA1125, and Tirzepatide. Lastly, Los Angeles California has 31 ongoing studies investigating treatments like PF-06865571 and Obeticholic Acid. These cities provide individuals with fatty liver disease access to cutting-edge clinical trials that pave the way for advancements in care and hope for better outcomes.
Which are the top treatments for fatty liver being explored in clinical trials?
Exciting advancements are underway in the exploration of treatments for fatty liver, with several potential options gaining attention in ongoing clinical trials. Leading the pack is semaglutide, currently being investigated in four active trials dedicated to combating this condition. Since its introduction in 2016, it has been involved in a total of 12 fatty liver trials, showcasing its promising potential. Another contender making waves is pioglitazone, with two active trials and a total of 14 all-time studies focused on fatty liver since its debut back in 2002. Rounding out the top treatments is EFX, which shows promise based on two active and three all-time clinical trials conducted since its listing as a treatment option for fatty liver patients just last year. As researchers delve deeper into these investigations, hope continues to build for effective interventions against this prevalent medical concern.
What are the most recent clinical trials for fatty liver?
Recent clinical trials hold promise in the field of fatty liver research, offering potential advancements in treatment options. One notable trial is Part 1 Group 2, which has reached Phase 2 and became available on September 14th, 2023. Another exciting study is the Reduction toward euinsulinemia (RE) protocol for fatty liver, currently at Phase 1 and accessible from August 29th, 2023 onwards. Additionally, LY3885125 (Part A), BI3006337 dose group 4, and Active Treatment: HU6 Planned doses of HU6 are all undergoing initial phases to evaluate their effectiveness in addressing fatty liver concerns. These recent clinical trials signify progress towards combating this prevalent condition and inspire hope for improved therapeutic interventions in the future.
What fatty liver clinical trials were recently completed?
Several clinical trials targeting fatty liver have recently come to a close, showcasing promising advancements in the field. Altimmune, Inc.'s ALT-801 therapy was investigated in two separate trials; one completed in September 2021 and another in March 2022. Other notable completed trials include BIO89-100 by 89bio, Inc. (August 2021), Efinopegdutide 20 mg/mL by Merck Sharp & Dohme Corp. (August 2021), AMG609 by Amgen (May 2021), TERN-201 by Terns, Inc. (May 2021), and JNJ-75220795 by Janssen Research & Development, LLC (April 2021). These study conclusions offer hope for patients with fatty liver disease as researchers strive towards effective treatments for this condition that affects millions worldwide.